Amuvatinib

DB12742InvestigationalSmall molecule

Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET... Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

Mechanism: Pharmacologically active on Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha, and Hepatocyte growth factor receptor
Curator reviewed
Primary indication: Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.Curator reviewed
Formula / weight: C₂₃H₂₁N₅O₃S · 447.51 g/mol (avg)
Also known as: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl- · 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-Carbothioamide · N-(1,3-Benzodioxol-5-ylmethyl)-4-(benzofuro(3,2-d)pyrimidin-4-yl)piperazine-1- carbothioamide
Code names: HPK-56 · MP-470

Resolves to

Compound

UNIISO9S6QZB4RCAS850879-09-3ChEMBLCHEMBL2103851ChEBI91389PubChem11282283

Structure

InChIKeyFOFDIMHVKGYHRU-UHFFFAOYSA-NSMILESS=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=C2C=CC=C1

Targets

P10721KITP16234PDGFRAP08581METP36888FLT3P07949RETQ06609RAD51

What you can answer from here — as of September 16, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amuvatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account